Synergistic Effect of Caffeine and Glucocorticoids on Expression of Surfactant Protein B (SP-B) mRNA

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Fehrholz, Markus ^a   Bersani, Iliana ^b   Kramer, Boris W ^c   Speer, Christian P ^a   Kunzmann, Steffen ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CAFFEINE; CYCLIC AMP; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLUCOCORTICOID RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HYDROCORTISONE; MESSENGER RNA; PHOSPHODIESTERASE; PREDNISOLONE; PREDNISONE; PROTEIN C JUN; ROLIPRAM; SURFACTANT PROTEIN B; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3;

ARTICLE; BIOACCUMULATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; INTRACELLULAR SPACE; LUNG ALVEOLUS EPITHELIUM; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; UPREGULATION;

CAFFEINE; CELL LINE, TUMOR; DEXAMETHASONE; DRUG SYNERGISM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HOMEOSTASIS; HUMANS; IMMUNOBLOTTING; PROMOTER REGIONS, GENETIC; PULMONARY SURFACTANT-ASSOCIATED PROTEIN B; RECEPTORS, GLUCOCORTICOID; RNA, MESSENGER; ROLIPRAM; TRANSCRIPTION FACTORS;

EID: 84871285619     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051575     Document Type: Article

References (66)

1. Perez-Gil JS, Weaver TE, (2010) Pulmonary surfactant pathophysiology: current models and open questions. Physiology (Bethesda) 25: 132-141.
2. Bersani I, Speer CP, Kunzmann S, (2012) Surfactant proteins A and D in pulmonary diseases of preterm infants. Expert Rev Anti Infect Ther 10: 573-584.
3. Ochs M, (2010) The closer we look the more we see? Quantitative microscopic analysis of the pulmonary surfactant system. Cell Physiol Biochem 25: 27-40.
4. Pérez-Gil J, (2008) Structure of pulmonary surfactant membranes and films: the role of proteins and lipid-protein interactions. Biochim Biophys Acta 1778: 1676-1695.
5. Weaver TE, Conkright JJ, (2001) Function of surfactant proteins B and C. Annu Rev Physiol. 63: 555-578.
6. Whitsett JA, Glasser SW, (1998) Regulation of surfactant protein gene transcription. Biochim Biophys Acta 1408: 303-311.
7. Liu W, Volpe MAV, Zscheppang K, Nielsen HC, Dammann CEL, (2009) ErbB4 regulates surfactant synthesis and proliferation in adult rat pulmonary epithelial cells. Exp Lung Res 35: 29-47.
8. Zscheppang K, Dörk T, Schmiedl A, Jones FE, Dammann CEL, (2011) Neuregulin Receptor ErbB4 Functions as a Transcriptional Cofactor for the Expression of Surfactant Protein B in the Fetal Lung. Am J Respir Cell Mol Biol 45: 761-767.
9. Berhane K, Boggaram V, (2001) Identification of a novel DNA regulatory element in the rabbit surfactant protein B (SP-B) promoter that is a target for ATF/CREB and AP-1 transcription factors. Gene 268: 141-151.
10. Alam MN, Berhane K, Boggaram V, (2002) Lung surfactant protein B promoter function is dependent on the helical phasing, orientation and combinatorial actions of cis-DNA elements. Gene 282: 103-111.
11. Whitsett JA, Wert SE, Weaver TE, (2010) Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu Rev Med 61: 105-119.
12. Speer CP, Robertson B, Curstedt T, Halliday HL, Compagnone D, et al. (1992) Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics 89: 13-20.
13. Speer CP, (2011) Neonatal respiratory distress syndrome: an inflammatory disease? Neonatology 99: 316-319.
14. Henderson-Smart DJ, De Paoli AG (2010) Methylxanthine treatment for apnoea in preterm infants. Cochrane Database Syst Rev 8.
15. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, et al. (2006) Caffeine therapy for apnea of prematurity. N Engl J Med 354: 2112-2121.
16. Harris MC, Baumgart S, Rooklin AR, Fox WW, (1983) Successful extubation of infants with respiratory distress syndrome using aminophylline. J Pediatr 103: 303-305.
17. Henderson-Smart DJ, Davis PG (2010) Prophylactic methylxanthines for endotracheal extubation in preterm infants. Cochrane Database Syst Rev 8.
18. Schmidt B, Roberts R, Millar D, Kirpalani H, (2008) Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants. Neonatology 93: 284-287.
19. Barnes PJ, (2005) Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc 2: 334-339.
20. Davis JK, Green JM, (2009) Caffeine and anaerobic performance: ergogenic value and mechanisms of action. Sports Med 39: 813-832.
21. Latini S, Pedata F, (2001) Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem 79: 463-484.
22. Valdez RC, Ahlawat R, Wills-Karp M, Nathan A, Ezell T, et al. (2011) Correlation between serum caffeine levels and changes in cytokine profile in a cohort of preterm infants. J Pediatr 158: 57-64, 64.e51.
23. Mukwevho E, Kohn TA, Lang D, Nyatia E, Smith J, et al. (2008) Caffeine induces hyperacetylation of histones at the MEF2 site on the Glut4 promoter and increases MEF2A binding to the site via a CaMK-dependent mechanism. Am J Physiol Endocrinol Metab 294: 15.
24. Ballard PL, Ballard RA, (1995) Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am J Obstet Gynecol 173: 254-262.
25. Lamontagne F, Briel M, Guyatt GH, Cook DJ, Bhatnagar N, et al. (2010) Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia: a meta-analysis of randomized controlled trials. J Crit Care 25: 420-435.
26. Thomas W, Speer CP, (2008) Nonventilatory strategies for prevention and treatment of bronchopulmonary dysplasia-what is the evidence? Neonatology 94: 150-159.
27. Glass CK, Ogawa S, (2006) Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol 6: 44-55.
28. Gupta S, Prasanth K, Chen CM, Yeh TF, (2012) Postnatal corticosteroids for prevention and treatment of chronic lung disease in the preterm newborn. Int J Pediatr 315642: 4.
29. Roberts D, Dalziel S (2006) Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 19.
30. Schmidt B, Roberts R, Millar D, Kirpalani H, (2008) Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants. Neonatology 93: 284-287.
31. Adcock IM, Ito K, Barnes PJ, (2004) Glucocorticoids: effects on gene transcription. Proc Am Thorac Soc 1: 247-254.
32. Brower M, Carney DN, Oie HK, Gazdar AF, Minna JD, (1986) Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res 46: 798-806.
33. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, et al. (1973) In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51: 1417-1423.
34. Kolla V, Gonzales LW, Gonzales J, Wang P, Angampalli S, et al. (2007) Thyroid transcription factor in differentiating type II cells: regulation, isoforms, and target genes. Am J Respir Cell Mol Biol 36: 213-225.
35. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
36. Salinas D, Sparkman L, Berhane K, Boggaram V, (2003) Nitric oxide inhibits surfactant protein B gene expression in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 285: L1153-L1165.
37. Frey FJ, Escher G, Frey BM, (1994) Pharmacology of 11 beta-hydroxysteroid dehydrogenase. Steroids 59: 74-79.
38. Liley HG, White RT, Warr RG, Benson BJ, Hawgood S, et al. (1989) Regulation of messenger RNAs for the hydrophobic surfactant proteins in human lung. J Clin Invest 83: 1191-1197.
39. O'Reilly MA, Clark JC, Whitsett JA, (1991) Glucocorticoid enhances pulmonary surfactant protein B gene transcription. Am J Physiol 260: L37-L43.
40. Vidaeff AC, Ramin SM, Gilstrap LC III, Alcorn JL, (2004) In vitro quantification of dexamethasone-induced surfactant protein B expression in human lung cells. J Matern Fetal Neonatal Med 15: 155-159.
41. Pilot-Matias TJ, Kister SE, Fox JL, Kropp K, Glasser SW, et al. (1989) Structure and organization of the gene encoding human pulmonary surfactant proteolipid SP-B. DNA 8: 75-86.
42. Boggaram V, (2003) Regulation of lung surfactant protein gene expression. Front Biosci 8: d751-d764.
43. Mendelson CR, (2000) Role of transcription factors in fetal lung development and surfactant protein gene expression. Annu Rev Physiol 62: 875-915.
44. Ballard PL, Gonzales LW, Williams MC, Roberts JM, Jacobs MM, (1991) Differentiation of type II cells during explant culture of human fetal lung is accelerated by endogenous prostanoids and adenosine 3′,5′-monophosphate. Endocrinology 128: 2916-2924.
45. Bates SR, Gonzales LW, Tao J-Q, Rueckert P, Ballard PL, et al. (2002) Recovery of rat type II cell surfactant components during primary cell culture. Am J Physiol Lung Cell Mol Physiol 282: L267-L276.
46. Gonzales LW, Guttentag SH, Wade KC, Postle AD, Ballard PL, (2002) Differentiation of human pulmonary type II cells in vitro by glucocorticoid plus cAMP. Am J Physiol Lung Cell Mol Physiol 283: L940-L951.
47. Floros J, Gross I, Nichols KV, Veletza SV, Dynia D, et al. (1991) Hormonal effects on the surfactant protein B (SP-B) mRNA in cultured fetal rat lung. Am J Respir Cell Mol Biol 4: 449-454.
48. Margana RK, Boggaram V, (1995) Transcription and mRNA stability regulate developmental and hormonal expression of rabbit surfactant protein B gene. Am J Physiol 268: L481-490.
49. Eickelberg O, Roth M, Lörx R, Bruce V, Rüdiger J, et al. (1999) Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 274: 1005-1010.
50. Essayan DM, (2001) Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 108: 671-680.
51. Alcorn JL, Smith ME, Smith JF, Margraf LR, Mendelson CR, (1997) Primary cell culture of human type II pneumonocytes: maintenance of a differentiated phenotype and transfection with recombinant adenoviruses. Am J Respir Cell Mol Biol 17: 672-682.
52. Takahashi Y, Izumi Y, Kohno M, Kawamura M, Ikeda E, et al. (2011) Airway administration of dexamethasone, 3′-5′-cyclic adenosine monophosphate, and isobutylmethylxanthine facilitates compensatory lung growth in adult mice. Am J Physiol Lung Cell Mol Physiol 300: L453-L461.
53. Sanz MJ, Cortijo J, Morcillo EJ, (2005) PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. Pharmacol Ther 106: 269-297.
54. Chung KF, (2006) Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 533: 110-117.
55. Woyda K, Koebrich S, Reiss I, Rudloff S, Pullamsetti SS, et al. (2009) Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia. Eur Respir J 33: 861-870.
56. de Visser YP, Walther FJ, Laghmani el H, Steendijk P, Middeldorp M, et al. (2012) Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats. Am J Physiol Lung Cell Mol Physiol 302: 23.
57. Whitsett JA, Matsuzaki Y, (2006) Transcriptional regulation of perinatal lung maturation. Pediatr Clin North Am 53: 873-887.
58. Boggaram V, (2009) Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung. Clin Sci 116: 27-35.
59. Losada A, Tovar JA, Xia HM, Diez-Pardo JA, Santisteban P, (2000) Down-regulation of thyroid transcription factor-1 gene expression in fetal lung hypoplasia is restored by glucocorticoids. Endocrinology 141: 2166-2173.
60. Yan C, Whitsett JA, (1997) Protein kinase A activation of the surfactant protein B gene is mediated by phosphorylation of thyroid transcription factor 1. J Biol Chem 272: 17327-17332.
61. Zscheppang K, Liu W, Volpe MV, Nielsen HC, Dammann CEL, (2007) ErbB4 regulates fetal surfactant phospholipid synthesis in primary fetal rat type II cells. Am J Physiol Lung Cell Mol Physiol 293: L429-L435.
62. Liu W, Purevdorj E, Zscheppang K, von Mayersbach D, Behrens J, et al. (2010) ErbB4 regulates the timely progression of late fetal lung development. Biochim Biophys Acta 1803: 832-839.
63. Beato M, (1989) Gene regulation by steroid hormones. Cell 56: 335-344.
64. Tissing WJ, Meijerink JP, Brinkhof B, Broekhuis MJ, Menezes RX, et al. (2006) Glucocorticoid-induced glucocorticoid-receptor expression and promoter usage is not linked to glucocorticoid resistance in childhood ALL. Blood 108: 1045-1049.
65. Föcking M, Schmiegelt D, Trapp T, (2005) Caffeine-mediated enhancement of glucocorticoid receptor activity in human osteoblastic cells. Biochem Biophys Res Commun 337: 435-439.
66. Boggaram V, Smith ME, Mendelson CR, (1991) Posttranscriptional regulation of surfactant protein-A messenger RNA in human fetal lung in vitro by glucocorticoids. Mol Endocrinol 5: 414-423.